Eligible AACR 2018 Annual Meeting Registrants will be sent access information after the Annual Meeting

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

clear all | select all

Conference Years:

clear all | select all

Days Within Meeting:

clear all | select all

Conferences:

Availability:

clear all | select all

Participation Type:

Presentations Access:

clear all | select all

Presentation Access:

clear all | select all

Topic Tracks*:

clear all | select all

Organ Site Tracks*:

Plenary Session 2: Defining and Targeting Cancer Neoepitopes

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 4 of 4
Plenary Session 2: Defining and Targeting Cancer Neoepitopes
Leveraging clinical genomics for candidate neoantigen discovery
Eliezer M. Van Allen
Dana-Farber Cancer Inst., Boston, MA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 8:00 AM-10:00 AM
Plenary Session 2: Defining and Targeting Cancer Neoepitopes
  •  
  • Paid users only
  • purchase
  • Coming soon
  • Some slides withheld
  •  
  •  
Building personal cancer vaccines
Patrick Ott
Dana-Farber Cancer Inst., Boston, MA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 8:00 AM-10:00 AM
Plenary Session 2: Defining and Targeting Cancer Neoepitopes
  •  
  • Paid users only
  • purchase
  • Available
  • Some slides withheld
  •  
  •  
Immunopeptidomics: Accelerating the development of personalized cancer immunotherapy
Michal Bassani-Sternberg
CHUV, Ludwig Cancer Research Center, Lausanne, Switzerland
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 8:00 AM-10:00 AM
Plenary Session 2: Defining and Targeting Cancer Neoepitopes
  •  
  • Paid users only
  • purchase
  • Available
  • All slides included
  •  
  •  
Insertion-and-deletion-derived tumor-specific neoantigens and the immunogenic phenotype: A pan-cancer analysis
Samra Turajlic
The Royal Marsden NHS Foundation Trust, London, United Kingdom
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 8:00 AM-10:00 AM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 4 of 4